arrow
E

Eric P. Hoffman

reveragen biopharma
H指数:113
被引数:5.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Muscle function, linear growth, and bone health during 30 months of vamorolone, prednisone, and deflazacort treatment for Duchenne muscular dystrophy: a comparative study

杜氏肌营养不良症治疗30个月期间vamorolone、泼尼松和去氟可的松治疗对肌肉功能、线性生长和骨骼健康的影响:一项比较研究

2026-10-290
OAAI
Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy

泼尼松,而非vamorolone,抑制与杜氏肌营养不良儿童生长迟缓相关的血清骨骼和软骨新型生物标志物

2026-08-030
OA
Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy

7至<18岁杜氏肌营养不良症男孩中vamorolone(VBP15-006)的II期开放标签、多次给药研究的成果

2026-03-030
OA
Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials

de Vera A, Clemens PR, Dang UJ, Dutreix C, Gresko E, Guglieri M, et al. 醛固酮受体拮抗作用:来自LIONHEART和VISION-DMD临床试验的证据。Steroids. (2025) 223:109689. doi: 10.1016/j.steroids.2025.109689。

2025-11-012
OAAI
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4-to <7-year children

vamorolone(一种解离性皮质类固醇抗炎药)对4至<7岁儿童血清生物标志物的暴露-反应关系

2025-11-010
OAAI
Lung Cancer Burden in the SPIROMICS Cohort.
2024-10-300
PRE
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy

Vamorolone在Duchenne肌营养不良症男孩中48周的疗效和安全性

2024-03-1211
OAAI
Moving Beyond the 2018 Minimum International Care Considerations for Osteoporosis Management in Duchenne Muscular Dystrophy (DMD): Meeting Report from the 3rd International Muscle-Bone Interactions Meeting 7th and 14th November 2022
2023-11-163
OAAI